Dysregulation in IFN-γ Signaling and Response: the Barricade to Tumor Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jun 5

PMID 37275859

Authors

Jiashu Han

Mengwei Wu

Ziwen Liu

Affiliations

Soon will be listed here.

Abstract

Interferon-gamma (IFN-γ) has been identified as a crucial factor in determining the responsiveness to immunotherapy. Produced primarily by natural killer (NK) and T cells, IFN-γ promotes activation, maturation, proliferation, cytokine expression, and effector function in immune cells, while simultaneously inducing antigen presentation, growth arrest, and apoptosis in tumor cells. However, tumor cells can hijack the IFN-γ signaling pathway to mount IFN-γ resistance: rather than increasing antigenicity and succumbing to death, tumor cells acquire stemness characteristics and express immunosuppressive molecules to defend against antitumor immunity. In this review, we summarize the potential mechanisms of IFN-γ resistance occurring at two critical stages: disrupted signal transduction along the IFNG/IFNGR/JAK/STAT pathway, or preferential expression of specific interferon-stimulated genes (ISGs). Elucidating the molecular mechanisms through which tumor cells develop IFN-γ resistance help identify promising therapeutic targets to improve immunotherapy, with broad application value in conjugation with targeted, antibody or cellular therapies.

Citing Articles

Interferon-driven Metabolic Reprogramming and Tumor Microenvironment Remodeling.

Chang T, Ho P Immune Netw. 2025; 25(1):e8.

PMID: 40078784 PMC: 11896656. DOI: 10.4110/in.2025.25.e8.

Tumor Prognostic Risk Model Related to Monocytes/Macrophages in Hepatocellular Carcinoma Based on Machine Learning and Multi-Omics.

Wan X, Zou Y, Zhou Q, Tang Q, Zhu G, Jia L Biol Proced Online. 2025; 27(1):9.

PMID: 40065214 PMC: 11892220. DOI: 10.1186/s12575-025-00270-9.

Clinical Characteristics Analysis of 30 Cases of Interferon-γ Autoantibody-Positive Patients with Concurrent Mycobacterial Infection: A 6-Year Retrospective Study.

Zhao C, Song C, He H, Huang X, Meng X, Huang A Infect Drug Resist. 2025; 18:1097-1110.

PMID: 40027921 PMC: 11871848. DOI: 10.2147/IDR.S493956.

An Immunogenic Cell Death-Related Gene Signature Predicts the Prognosis and Immune Infiltration of Cervical Cancer.

Sun F, Sun Y, Tian H Cancer Inform. 2025; 24:11769351251323239.

PMID: 40008391 PMC: 11851768. DOI: 10.1177/11769351251323239.

Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back.

Mariniello A, Borgeaud M, Weiner M, Frisone D, Kim F, Addeo A BioDrugs. 2025; 39(2):215-235.

PMID: 39954220 PMC: 11906525. DOI: 10.1007/s40259-024-00700-2.

References

Yeh H, Yu C, Yang H, Ko S, Liao C, Lin Y . Ubiquitin-specific protease 13 regulates IFN signaling by stabilizing STAT1. J Immunol. 2013; 191(6):3328-36. DOI: 10.4049/jimmunol.1300225. View

Jefferies C . Regulating IRFs in IFN Driven Disease. Front Immunol. 2019; 10:325. PMC: 6449421. DOI: 10.3389/fimmu.2019.00325. View

Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H . Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene. 2004; 23(55):8876-86. DOI: 10.1038/sj.onc.1208144. View

Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay R, Luoma A . A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018; 359(6377):770-775. PMC: 5953516. DOI: 10.1126/science.aao1710. View

Zaidi M . The Interferon-Gamma Paradox in Cancer. J Interferon Cytokine Res. 2018; 39(1):30-38. PMC: 6350411. DOI: 10.1089/jir.2018.0087. View

Zhang Y, Chen Y, Liu Z, Lai R . ERK is a negative feedback regulator for IFN-γ/STAT1 signaling by promoting STAT1 ubiquitination. BMC Cancer. 2018; 18(1):613. PMC: 5984314. DOI: 10.1186/s12885-018-4539-7. View

Curtsinger J, Agarwal P, Lins D, Mescher M . Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-α to stimulate strong function. J Immunol. 2012; 189(2):659-68. PMC: 3392455. DOI: 10.4049/jimmunol.1102727. View

Schoggins J, Wilson S, Panis M, Murphy M, Jones C, Bieniasz P . A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481-5. PMC: 3409588. DOI: 10.1038/nature09907. View

Larkin 3rd J, Johnson H, Subramaniam P . Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of the IFN-gamma receptor complex following activation by IFN-gamma. J Interferon Cytokine Res. 2000; 20(6):565-76. DOI: 10.1089/10799900050044769. View

10.

von Locquenghien M, Rozalen C, Celia-Terrassa T . Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J Clin Invest. 2021; 131(1). PMC: 7773346. DOI: 10.1172/JCI143296. View

11.

Londino J, Gulick D, Lear T, Suber T, Weathington N, Masa L . Post-translational modification of the interferon-gamma receptor alters its stability and signaling. Biochem J. 2017; 474(20):3543-3557. PMC: 5967388. DOI: 10.1042/BCJ20170548. View

12.

Kaplan D, Shankaran V, Dighe A, STOCKERT E, Aguet M, Old L . Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998; 95(13):7556-61. PMC: 22681. DOI: 10.1073/pnas.95.13.7556. View

13.

Chen J, Du M, Li W, Lei C, Yang B, Tang H . [The relationship between CD4(-) CD8(-) T cells in the peripheral blood of patients with pancreatic carcinoma and IL-4, IFN-gamma levels]. Zhonghua Wai Ke Za Zhi. 2009; 47(13):995-8. View

14.

Cui K, Chen Z, Cao Y, Liu S, Ren G, Hu G . Restraint of IFN-γ expression through a distal silencer CNS-28 for tissue homeostasis. Immunity. 2023; 56(5):944-958.e6. PMC: 10175192. DOI: 10.1016/j.immuni.2023.03.006. View

15.

Li X, Jiang W, Dong S, Li W, Zhu W, Zhou W . STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules. 2022; 12(10). PMC: 9599947. DOI: 10.3390/biom12101450. View

16.

Kano A, Haruyama T, Akaike T, Watanabe Y . IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem Biophys Res Commun. 1999; 257(3):672-7. DOI: 10.1006/bbrc.1999.0276. View

17.

Ghosh P, Antretter H . Left coronary artery system source diseases. Surgical issues. J Cardiovasc Surg (Torino). 1990; 31(3):298-304. View

18.

Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lemaitre F . A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021; 6(57). DOI: 10.1126/sciimmunol.abd4344. View

19.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

20.

Andrianifahanana M, Singh A, Nemos C, Ponnusamy M, Moniaux N, Mehta P . IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response. Oncogene. 2007; 26(51):7251-61. DOI: 10.1038/sj.onc.1210532. View